Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/12 cls
Alnylam (ALNY) Piper Jaffray Edward Tenthoff Downgrade Market perform (from market outperform) 3% $35.43
Tenthoff thinks positive Phase IIa results for ALNY's ALN-RSV01 to treat and prevent respiratory syncytial virus (RSV) are already priced into the stock. He expects data for the RSV-specific siRNA by year end. Tenthoff kept his $30 price target.

Read the full 667 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers